Cancer immunotherapy has shown promising results although a significant proportion of patients respond poorly or relapse at a later stage, therefore more potent combination therapies are required. Tumor ablation by Photodynamic Therapy (PDT) can strongly reduce tumor mass and induce the release of tumor antigen and pro-inflammatory mediators, therefore being an attractive option for combination with immunotherapy. In this preclinical study, we show that tumor-specific immunotherapy by synthetic long peptide (SLP) vaccination can be efficiently Indeed, PDT by itself induced a significant CD8 + T cell response against the tumor, which was increased when combined with SLP vaccination and essential for the therapeutic effect of combination therapy.
Introduction
A major challenge in medical oncology is the development of efficient treatment options for advanced cancer, which currently are limited. The clinical situation of advanced primary tumors with possible metastases asks for therapeutic protocols that combine a strong anti-tumor effect to eradicate known tumors with the induction of a systemic anti-tumor immune response to eliminate distant metastases. As the immune system can strongly and specifically attack targets based on the principle of antigen-specificity, cancer immunotherapy aims to employ these characteristics of the immune system to attack and eradicate tumors.
A promising approach of cancer immunotherapy is therapeutic vaccination using synthetic long peptides (SLP) covering T cell epitopes of tumor antigens (1) (2) (3) (4) . Besides widely shared tumor antigens such as those expressed by virally induced tumors, this approach can also be applied to individual patient-specific neo-antigens (5, 6) . Clinical studies using therapeutic SLP vaccination against cancer are ongoing based on encouraging results in preclinical tumor models (7) (8) (9) . For instance, clinical Phase I/II studies using a set of overlapping peptides covering the E6 and E7 oncoproteins of Human Papillomavirus 16 (HPV16) have been successful in patients with HPV16-induced premalignant disease (10) . This peptide vaccine formulation induced HPV16-specific T cell responses in all 20 patients and resulted in clinical responses in about 80% of patients and nearly 50% complete remissions correlating with robust effector T cell immunity. However, thus far this vaccine was not clinically effective against established HVP16
+ cancer despite detectable vaccine-induced T cell responses (11, 12) . This use of Photodynamic Therapy (PDT), a tumor ablation method that is widely clinically applied for various premalignant and malignant lesions.
In PDT, an inactive light-sensitive molecule called photosensitizer is administered and subsequently activated by irradiation of the target area with visible light of a specific wavelength.
The activated photosensitizer reacts with oxygen to form reactive oxygen species (ROS), which induce tumor cell death and vascular shutdown (13, 14) . Besides direct cytotoxic effects on tumor cells, PDT has been shown to cause the release of antigen and immunogenic factors such as damage-associated molecular patterns (DAMPs) from dying tumor cells (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . These immunological effects make PDT an attractive option for combinations with immunotherapy in the treatment of advanced tumors. Here, we use Bremachlorin, also known as Radachlorin, a novel photosensitizer that benefits from improved pharmacokinetics and high-wavelength irradiation reaching deeper tissue. Bremachlorin is currently being tested in clinical trials for basal cell carcinoma (BCC) and non-small-cell lung carcinoma (NSCLC) (26) (27) (28) (29) (30) (31) .
In this study we investigated the combination of Bremachlorin-based PDT with therapeutic peptide vaccination in two mouse models of highly aggressive subcutaneous tumors. The tumor line TC-1 expresses the E6 and E7 oncoproteins of Human Papillomavirus 16 (HPV16) as a model for human HPV16-induced tumors, and has previously been shown to be sensitive for Bremachlorin-PDT (32, 33) . RMA is an aggressive T cell lymphoma cell line induced by Rauscher murine leukemia virus (34) . We show that PDT strongly ablated established fastgrowing tumors, leading to a significantly longer survival and specific CD8 + T cell responses against the tumor. Combining PDT with therapeutic peptide vaccination efficiently eradicated established tumors, which was dependent on the presence of CD8 + T cells. Importantly, combination treatment of primary tumors led to subsequent eradication of distant established secondary tumors and provided protection against repeated tumor challenge. Therefore, this successful combination of PDT and therapeutic vaccination, resulting in robust anti-tumor response and immunological memory, suggests a novel therapeutic combination strategy for advanced cancer.
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Materials and Methods

Mice and cell lines
Wildtype C57BL/6 mice were obtained from Charles River Laboratories (France). Albino B6 mice (tyrosinase-deficient immunocompetent C57BL/6 mice) were bred in the animal breeding facility of the Leiden University Medical Center, the Netherlands. All experiments were approved by the animal ethical committee of the University of Leiden. The TC-1 mouse tumor cell line (a gift from T.C. Wu, John Hopkins University, Baltimore, MD) expressing HPV16 E6 and E7 oncoproteins was generated as previously described (32) . RMA is a mutagenized derivative of RBL-5, a Rauscher Murine Leukemia Virus (MuLV)-induced T cell lymphoma line of C57BL/6 origin (34). Cell lines were assured to be free of rodent viruses and Mycoplasma by regular PCR analysis. Authentication of the cell lines was done by antigen-specific T-cell recognition and cells of low passage number were used for all experiments. TC-1 cells were cultured as previously described (35) . RMA cells were cultured in IMDM (Lonza) containing 8% Fetal Calf Serum (FCS, Greiner), 100 IU/mL penicillin/streptomycin (Gibco), 2 mM glutamin (Gibco) and 
Photodynamic Therapy
Tumors were treated 9 days (TC-1) or 14 days (RMA) after inoculation, both at an average tumor diameter of 5 mm. First, 20 mg/kg Bremachlorin photosensitizer (RadaPharma International, 0.35% in SWFI, average 100 µL) was injected intravenously in the tail vein, followed by irradiation of the tumor 6 hours later using a 662 nm Milon Lakhta laser. The 6 hour interval was selected based on drug-light timing experiments, and has been described to result in a predominantly vascular localization of Bremachlorin (29) . A continuous irradiation protocol of 1000 seconds at 116 mW/cm 2 (116 J/cm 2 ) was used based on optimization experiments (data not shown). For irradiation, the skin in the tumor area was shaved and the mice were anaesthetized by inhalation of isoflurane and positioned horizontally on a heat mat. Precision irradiation of the tumor was ensured by using a fiber fixed vertically above the mouse, and the exposed area was precisely adjusted using a diaphragm.
Serum analysis for HMGB1
Serum was obtained from blood samples taken 1 hour after PDT treatment, or at the same time for untreated controls. The HMGB1 serum level was determined by a sandwich ELISA kit (IBL International) following the manufacturers protocol.
Ex vivo lymph node analysis
TC-1 tumor-bearing animals received the standard PDT treatment as described above, and were sacrificed after 6 days and the tumor-draining inguinal lymph node was obtained, together with the contralateral inguinal lymph node. The lymph nodes were incubated with 2.5 mg/mL Liberase TL (Roche) for 20 minutes at 37°C and single-cell suspensions were made using 70 µm cell strainers (BD Biosciences). The cells were then stained with fluorescently labeled antibodies against CD3ε, CD8α, CD11c and with 7-AAD and APC-labeled tetramer for flow cytometry analysis.
Flow cytometry
All flow cytometry analyses were performed by suspending cells in FACS buffer (PBS with 0.5% BSA and 0.02% sodium azide) and analysis on a BD FACS Calibur. Antibodies against CD3, CD8 or CD11c and the dyes Annexin V and 7-AAD were purchased from BD, eBioscience and BioLegend. The APC-labelled H-2Db RAHYNIVTF tetramer was own production.
Synthetic long peptide vaccination
The SLP vaccine for TC-1 (sequence GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR), including both a CD4 and a CD8 epitope from the HPV16 E7 oncoprotein, was given on day 7 
Systemic blood analysis for specific CD8 + T cell response
The systemic tumor-specific CD8 + T cell response was determined by taking venous blood samples from the tail vein 8 days after peptide vaccination or on the same day for nonvaccinated animals. After erythrocyte lysis of the blood samples, the tumor-specific CD8 + T cell response was determined by flow cytometry analysis after staining of the cells with CD3ε, CD8β, and APC-conjugated tetramers for the relevant peptide-MHC complex on the CD8 + T cell.
CD8 + T cell depletion
Hybridoma cells producing depleting CD8 mAb (clone 2.43) were cultured in Protein-Free Hybridoma Medium (Gibco), and mAbs were purified using a Protein G column. To deplete CD8 + T cells, mice received an intraperitoneal (i.p.) injection of 150 µg anti-CD8 antibodies on day 8 after tumor inoculation, followed by periodical depletion by 50 µg antibody every 5 days until day 30 after tumor inoculation. All control mice received in parallel similar amounts of isotype control rat immunoglobulin G. Efficient T-cell depletion was assured by flow cytometry analysis of blood lymphocytes stained for cell surface expression of CD8.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.0 software. Data are shown
Research. as the mean ± SEM for each group, and comparison of groups was performed by two-tailed Student's t-test, with the exception of survival curves which were compared using the LogRank Mantel-Cox test. Statistical differences were considered significant at p < 0.05.
Results
Efficient photosensitizer uptake allows strong tumor ablation
For effective PDT, sufficient photosensitizer uptake by tumor cells is required to ensure irradiation-induced cell death. Both TC-1 and RMA tumor cells showed a dose-dependent uptake after incubation with Bremachlorin ( Supplementary Fig. S1a ). Irradiation of Bremachlorin-treated TC-1 cells using visible light resulted in >98% cell death based on Annexin V and 7-AAD analysis, which was completely dependent on the presence of both the photosensitizer and the irradiation (Supplementary Fig. S1b ). Photosensitizer uptake in established tumors was shown by intravenously injecting mice bearing subcutaneous TC-1 or RMA tumors with Bremachlorin, which after 6 hours accumulated in the tumor area (Supplementary Fig. S2 ). To analyze whether this photosensitizer accumulation is sufficient for photodynamic ablation, growing TC-1 tumors with a diameter of 5 mm were irradiated with a focused laser beam 6 hours after injection of Bremachlorin. After a clear inflammatory reaction in the treated area in the first days after PDT, a strongly flattened tumor lesion remained with a necrotic appearance. This resulted in a significant delay in tumor growth of at least 7 days, after which tumor outgrowth resumed with a growth rate similar to untreated tumors (Fig. 1a) .
PDT induces an anti-tumor immune response
As we aimed to use Bremachlorin-based PDT in combination with immunotherapy, we analyzed (Fig. 1b) . To investigate the immunological consequences of the massive tumor cell death induced by PDT, we analyzed the tumor-draining lymph nodes 6 days after PDT treatment of TC-1 tumors and compared them to contralateral lymph nodes not draining the irradiated tumor area. PDT induced a strong tumor antigenspecific CD8 + T cell response in the tumor-draining lymph nodes, accompanied by a significant increase in the total number of CD8 + T cells which was not increased in the non-draining nodes of the same animals (Fig. 1c) . Untreated tumor-bearing mice mounted only a minimal CD8 + T cell response against the tumor, quantitatively similar to non-draining lymph nodes of PDTtreated mice. Strikingly, also the numbers of CD11c + dendritic cells (DC) were strongly increased in the draining nodes of the PDT-treated tumor, suggesting that the DC facilitate cross-presentation of tumor-associated antigen to T cells in local lymphoid organs to stimulate anti-tumor responses.
Combination of PDT and therapeutic vaccination eradicates established tumors
Altogether, the strong tumor ablation and beneficial immunological effects of Bremachlorin-PDT make it an attractive candidate for combination with immunotherapy. As we have previously
shown that the TC-1 tumor model is susceptible to therapeutic synthetic long peptide (SLP)
vaccination (7), we combined Bremachlorin-PDT with SLP vaccination following the experimental setup depicted in Supplementary Figure S3 . Single treatments of PDT or peptide vaccination of established TC-1 tumors each resulted in a significant delay in tumor outgrowth and increased survival, but neither treatment was curative. However, when PDT was combined with SLP vaccination, overall survival was strongly increased and over one third of mice were cured (Fig. 2) .
Combination treatment protects against tumor rechallenge and eradicates established secondary tumors
Research. Fig. S4a ). To investigate whether combination therapy can also eradicate existing established distant tumors, mice were inoculated with TC-1 tumors in both flanks followed by combination therapy where PDT was only applied on the primary tumor in the right flank, as depicted in Supplementary Figure S4b . The outgrowth of secondary tumors was not delayed by PDT of the contralateral primary tumor (Fig. 3a) . Mice treated by peptide vaccination showed an initial regression of both primary and secondary tumors, after which nearly all tumors resumed to grow out. In contrast, combination treatment of PDT and peptide vaccination caused definite cure from both primary and secondary tumors in over 30% of mice, significantly higher than peptide vaccination alone. (Fig. 3b) .
Treatment-induced anti-tumor CD8 + T cells are essential for therapeutic efficacy
As we found that PDT induces a local immune response in lymph nodes and that combination therapy using local PDT is also able to cure distant secondary tumors, we analyzed the systemic CD8 + T cell response against the tumor. Using specific MHC tetramer staining to identify tumor antigen-specific CD8 + T cells, we could show that SLP vaccination raised the levels of CD8 + T cells specific for the HVP16 E7 epitope used for vaccination in circulating blood as we have reported previously (Fig. 4a) (7) . Importantly, also PDT significantly increased experiment (data not shown). In the absence of CD8 + T cells, the curative effect of PDT and SLP combination treatment was abrogated, suggesting a crucial role of CD8 + T cells in this combination treatment protocol (Fig. 4b) .
Efficient PDT-vaccination combination in virally-induced lymphoma tumors
Next, we applied PDT and peptide vaccination in another aggressive tumor system, the RMA lymphoma model for which we have previously described efficient prophylactic peptide vaccination, which prevented tumor outgrowth through the effects of both CD4 + and CD8 + T cells (36) . Previous attempts in our group to treat established RMA tumors by therapeutic peptide vaccination have never been successful. Here, we show that combination of Bremachlorin-PDT and therapeutic peptide vaccination in mice bearing subcutaneous RMA tumors resulted in significantly prolonged survival compared to either single treatment alone, similar to our observations in the TC-1 model (Fig. 5) . All mice cured of their primary tumor were able to reject RMA tumor cells upon rechallenge at a distant location over two months after treatment (data not shown), suggesting that also in this model PDT and peptide vaccination induced systemic immunity against the tumor.
Discussion
In this study we suggest a novel therapeutic combination strategy for advanced metastatic cancer, consisting of PDT-mediated tumor ablation and tumor-specific peptide vaccination. In two independent aggressive tumor models we show that ablation of established tumors using Several animal tumor models expressing known tumor antigens are available to study the immunological effects of PDT on an antigen-specific level; however, many concern artificially introduced model antigens such as chicken ovalbumin which have no clinical relevance (19) . To overcome this limitation, a recent study used a murine mastocytoma tumor expressing P1A, the mouse homolog of human MAGE cancer/testis antigens, and showed antigen-specific immune responses against this clinically relevant tumor antigen and corresponding effects on tumor growth (37) . In this study, we used two mouse tumor models expressing known epitopes from oncogenic viruses as a model for HPV-or Leukemia Virus-induced cancer in humans, and showed successful combination treatment of these tumors by PDT and peptide vaccination. (38, 39) . Importantly, the application of combination therapy using PDT and SLP vaccination may theoretically be extended to virtually any type of cancer, as was illustrated by recent studies identifying neo-epitopes, which are mutated sequences in 'self' proteins acquired by tumor cells, allowing 'non-self'-peptide/MHC recognition by specific T cells. Therapeutic vaccination with long peptides containing these tumor-specific neo-epitopes has proven successful in preclinical studies (5, 6) . 
